
Please try another search
Durect Corporation is a biopharmaceutical company that is focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The Company is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The Company focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug. CLOUD is a class of bioerodible injectable depot technology.
Name | Age | Since | Title |
---|---|---|---|
James E. Brown | 64 | 1998 | Co-Founder, CEO, President & Director |
Gail J. Maderis | 66 | 2021 | Independent Chairman of the Board |
Terrence F. Blaschke | 80 | 2006 | Independent Director |
Mohammad Azab | 67 | 2021 | Independent Director |
Peter S. Garcia | 61 | 2021 | Independent Director |
Gail M. Farfel | 59 | 2019 | Director |
Judith J. Robertson | 63 | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review